Repligen extended its long-term supply agreement with Purolite for the development and manufacturing of affinity ligands focused on monoclonal antibodies and antibody fragments. The Repligen exclusive agreement, entered into with Purolite in 2018 for the development and supply of NGL-Impact® Protein A ligands, extends the partnership to 2032 and broadens the scope of the agreement to now include ligands targeting mAb fragments, according to Tony J. Hunt, president and CEO of Repligen.
“We are delighted with the progress we have made working with Purolite and now Ecolab to establish the NGL family of Protein A ligands in the marketplace,” he said. “This extension and product line expansion is well aligned with our proteins strategy and supports the acceleration in market adoption of the Praesto® affinity resin portfolio.
“Additionally, Repligen will continue to receive access to Purolite’s base-bead technology, as we proceed with the development and commercialization of novel affinity resins focused on new modalities and gene therapy.”